OMEPRAZOLE; SODIUM BICARBONATE
| Brand name | KONVOMEP |
|---|---|
| Active ingredient | OMEPRAZOLE; SODIUM BICARBONATE |
| Strength | 2MG/ML;84MG/ML |
| Dosage form | FOR SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | August 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11771686 | March 2040 | use U-623 |
| 12440566 | July 2039 | product |
| 12329752 | July 2039 | product |
| 11103492 | July 2039 | product |
| 11633478 | July 2039 | product |
| 12042539 | July 2039 | product |
| 11911473 | July 2039 | use U-624 |
| 10751333 | July 2039 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.